New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation DOI Creative Commons
Walid E. Elgammal, Hazem Elkady, Reda G. Yousef

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(18), P. 14477 - 14498

Published: Jan. 1, 2025

Vascular endothelial growth factor receptor-2 (VEGFR-2) is a key regulator of tumor angiogenesis and has become an important target in anticancer drug development.

Language: Английский

New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation DOI Creative Commons
Walid E. Elgammal, Hazem Elkady, Reda G. Yousef

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(18), P. 14477 - 14498

Published: Jan. 1, 2025

Vascular endothelial growth factor receptor-2 (VEGFR-2) is a key regulator of tumor angiogenesis and has become an important target in anticancer drug development.

Language: Английский

Citations

0